Most people with hepatitis C go untreated, despite effective drugs

December 10, 2012 by Laura Kennedy

Just 20 percent of people infected with the hepatitis C virus (HCV) begin the recommended treatment regimen and less than 5 percent go on to successfully overcome the virus, according to a new review in General Hospital Psychiatry. This is despite the availability of highly effective anti-viral drugs that clear hepatitis C virus in about 80 percent of patients participating in clinical trials. Major barriers to recommended care are substance abuse and depression in HCV patients.

Other barriers to treatment include patients' attitudes toward treatment, including a fear of the side effects associated with some of the anti-viral drugs and an inability or unwillingness to abstain from drugs or alcohol, which is required for successful treatment.

As many as 4 million Americans have , which is a blood-borne viral infection that is the most common cause of severe liver disease and in the United States. In the past, hepatitis C was sometimes transmitted during medical procedures such as blood transfusions but this risk has been significantly reduced. The illicit use of injection drugs is the primary source of new infections.

People who engage in high-risk behavior in their youth often don't realize they have HCV until they reach middle age and are diagnosed with end-stage liver disease, said Barry Hong, Ph.D., of Washington University School of Medicine in St. Louis, a coauthor of the review. Recently, the Centers for Disease Control and Prevention recommended that all be screened for HCV.

"Screening patients with psychiatric and substance use disorders is also a must," notes Muhamad Aly Rifai, M.D., a psychiatrist specializing in mental illness and at the Commonwealth Medical College in Pennsylvania.

The findings suggest that many of these barriers to care can be readily addressed through education or by treating patients' mental conditions before or during treatment for HCV, including the use of anti-depressants, the authors suggest.

In addition to their high risk health behaviors, many also face practical barriers to accessing treatment such as lack of transportation, good social supports, or adequate housing. The authors recommend providing a multidisciplinary treatment approach that involves social workers, physician assistants and others to provide assistance.

The review also "underscores the need for better anti-HCV regimens with fewer side effects," notes Frederick Askari, M.D., Ph.D., a hepatologist at the University of Michigan Medical Center. "Fortunately better treatments are on the horizon, with over 20 promising compounds in various stages of clinical development."

Explore further: Researcher Announced Cure for Hepatitis C

More information: North C., et al. Hepatitis c treatment and SVR: the gap between clinical trials and real-world treatment aspirations. General Hospital Psychiatry, 2012.

Related Stories

Researcher Announced Cure for Hepatitis C

May 22, 2007

The use of peginterferon alone, or in combination with ribavirin, points to a cure for hepatitis C, the leading cause of cirrhosis, liver cancer and the need for liver transplant, a Virginia Commonwealth University researcher ...

Keeping hepatitis C virus at bay after a liver transplant

October 1, 2009

One of the most common reasons for needing a liver transplant is liver failure or liver cancer caused by liver cell infection with hepatitis C virus (HCV). However, in nearly all patients the new liver becomes infected with ...

New vaccine for hepatitis C virus

July 28, 2011

Murdoch University researchers have begun a study to develop a new and innovative vaccine for the hepatitis C virus (HCV).

Recommended for you

In sub-Saharan Africa, cancer can be an infectious disease

August 26, 2016

In 1963, Irish surgeon Denis Parson Burkitt airmailed samples of an unusual jaw tumor found in Ugandan children to his colleague, Anthony Epstein, at Middlesex Hospital in London. Epstein, an expert in chicken viruses and ...

Zika virus may persist in the vagina days after infection

August 25, 2016

The Zika virus reproduces in the vaginal tissue of pregnant mice several days after infection, according to a study by Yale researchers. From the genitals, the virus spreads and infects the fetal brain, impairing fetal development. ...

Team discovers how Zika virus causes fetal brain damage

August 24, 2016

Infection by the Zika virus diverts a key protein necessary for neural cell division in the developing human fetus, thereby causing the birth defect microcephaly, a team of Yale scientists reported Aug. 24 in the journal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.